Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) Director Sells 205,847 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director Theodore Leonsis sold 205,847 shares of the firm's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $67.66, for a total transaction of $13,927,608.02. Following the transaction, the director now directly owns 15,511 shares of the company's stock, valued at $1,049,474.26. The trade was a 92.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Tempus AI Trading Down 0.0%

Shares of NASDAQ:TEM traded down $0.01 during trading on Friday, hitting $71.22. 12,804,122 shares of the company's stock were exchanged, compared to its average volume of 7,004,840. Tempus AI, Inc. has a 1-year low of $22.89 and a 1-year high of $91.45. The firm has a 50-day moving average price of $55.90 and a two-hundred day moving average price of $52.39. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The firm has a market cap of $12.33 billion and a P/E ratio of -9.13.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. The business had revenue of $255.74 million for the quarter, compared to analyst estimates of $248.13 million. The company's revenue for the quarter was up 75.4% on a year-over-year basis. Equities analysts predict that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. BTIG Research assumed coverage on shares of Tempus AI in a research report on Monday, April 21st. They set a "buy" rating and a $60.00 target price for the company. William Blair reiterated a "market perform" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Wolfe Research cut shares of Tempus AI from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Guggenheim reiterated a "buy" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Finally, Bank of America raised their price objective on shares of Tempus AI from $48.00 to $68.00 and gave the company a "neutral" rating in a research report on Tuesday, May 20th. Six investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $63.42.

Institutional Investors Weigh In On Tempus AI

Several institutional investors have recently modified their holdings of TEM. Mirae Asset Global Investments Co. Ltd. acquired a new position in Tempus AI during the fourth quarter valued at approximately $178,000. Apollon Wealth Management LLC acquired a new position in Tempus AI during the fourth quarter valued at approximately $256,000. Private Advisor Group LLC acquired a new position in Tempus AI during the fourth quarter valued at approximately $1,344,000. Sigma Planning Corp grew its holdings in Tempus AI by 43.9% during the fourth quarter. Sigma Planning Corp now owns 33,638 shares of the company's stock valued at $1,136,000 after purchasing an additional 10,269 shares during the period. Finally, First Horizon Advisors Inc. grew its holdings in Tempus AI by 207.9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock valued at $55,000 after purchasing an additional 1,108 shares during the period. Institutional investors and hedge funds own 24.22% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.